5 7

Cited 0 times in

Cited 0 times in

Romosozumab Enhances Implant Stability in Glucocorticoid-Induced Osteoporotic Bone: A Rabbit Model Study

DC Field Value Language
dc.contributor.authorKwon, Ji-won-
dc.contributor.authorMoon, Seong-hwan-
dc.contributor.authorSuk, Kyung-soo-
dc.contributor.authorPark, Si-young-
dc.contributor.authorKim, Hak-sun-
dc.contributor.authorPark, Sub-ri-
dc.contributor.authorKim, Namhoo-
dc.contributor.authorLee, Byungho-
dc.date.accessioned2026-02-02T05:33:34Z-
dc.date.available2026-02-02T05:33:34Z-
dc.date.created2026-01-30-
dc.date.issued2025-12-
dc.identifier.issn2586-6583-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/210438-
dc.description.abstractObjective: Implant fixation in osteoporotic bone presents substantial challenges due to reduced bone mass and compromised microarchitecture. This study investigated whether romosozumab, a sclerostin inhibitor, improves osseointegration and mechanical stability of cancellous bone screws in glucocorticoid-induced osteoporosis. Methods: Fifty-five New Zealand white rabbits were enrolled. Osteoporosis was induced via either bilateral ovariectomy or weekly intramuscular glucocorticoid injections (4–8 mg/kg). Based on bone mineral density results, glucocorticoid injection was selected for experimental induction. Rabbits were divided into 5 groups: control, untreated osteoporosis, parathyroid hormone (PTH), PTH combined with denosumab, and romosozumab. Cancellous bone screws (4.0-mm diameter, titanium alloy) were bilaterally inserted into the iliac bones. Antiosteoporosis treatments were administered for 3-week postimplantation. Histomor-phometric evaluation of bone-to-implant contact (BIC) and bone area fraction occupancy (BAFO) was performed using nondecalcified sectioning and Goldner trichrome staining. Biomechanical pull-out testing measured resistance at 1-mm displacement using a standardized setup on the MTS system. Results: The romosozumab-treated group exhibited superior outcomes. BIC reached 21.2% ± 18.1%, and BAFO was 56.9% ± 9.9%. Pull-out strength significantly increased to 275 ± 55 N in the romosozumab group, outperforming PTH (184 ± 61 N), PTH+denosumab (202 ± 23 N), and untreated osteoporosis (120 ± 33 N). Enhanced collagen structure and neobone formation were observed histologically around implants. Conclusion: Romosozumab significantly enhances cancellous bone screw fixation strength and osseointegration in glucocorticoid-induced osteoporotic bone. These findings suggest its clinical potential as an adjuvant therapy in improving spinal implant outcomes in osteoporotic patients. © 2025 by the Korean Spinal Neurosurgery Society.-
dc.languageEnglish-
dc.publisherKorean Spinal Neurosurgery Society-
dc.relation.isPartOfNeurospine-
dc.relation.isPartOfNEUROSPINE-
dc.titleRomosozumab Enhances Implant Stability in Glucocorticoid-Induced Osteoporotic Bone: A Rabbit Model Study-
dc.typeArticle-
dc.contributor.googleauthorKwon, Ji-won-
dc.contributor.googleauthorMoon, Seong-hwan-
dc.contributor.googleauthorSuk, Kyung-soo-
dc.contributor.googleauthorPark, Si-young-
dc.contributor.googleauthorKim, Hak-sun-
dc.contributor.googleauthorPark, Sub-ri-
dc.contributor.googleauthorKim, Namhoo-
dc.contributor.googleauthorLee, Byungho-
dc.identifier.doi10.14245/ns.2550774.387-
dc.relation.journalcodeJ03945-
dc.identifier.eissn2586-6591-
dc.identifier.pmid41508577-
dc.subject.keywordGlucocorticoid-
dc.subject.keywordImplant-
dc.subject.keywordOsteoporosis-
dc.subject.keywordRabbit-
dc.subject.keywordRomosozumab-
dc.contributor.affiliatedAuthorKwon, Ji-won-
dc.contributor.affiliatedAuthorMoon, Seong-hwan-
dc.contributor.affiliatedAuthorSuk, Kyung-soo-
dc.contributor.affiliatedAuthorPark, Si-young-
dc.contributor.affiliatedAuthorKim, Hak-sun-
dc.contributor.affiliatedAuthorPark, Sub-ri-
dc.contributor.affiliatedAuthorKim, Namhoo-
dc.contributor.affiliatedAuthorLee, Byungho-
dc.identifier.scopusid2-s2.0-105027765702-
dc.identifier.wosid001667773700002-
dc.citation.volume22-
dc.citation.number4-
dc.citation.startPage880-
dc.citation.endPage890-
dc.identifier.bibliographicCitationNeurospine, Vol.22(4) : 880-890, 2025-12-
dc.identifier.rimsid91452-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorGlucocorticoid-
dc.subject.keywordAuthorImplant-
dc.subject.keywordAuthorOsteoporosis-
dc.subject.keywordAuthorRabbit-
dc.subject.keywordAuthorRomosozumab-
dc.subject.keywordPlusPOSTMENOPAUSAL OSTEOPOROSIS-
dc.subject.keywordPlusSCLEROSTIN-
dc.subject.keywordPlusWOMEN-
dc.subject.keywordPlusFUSION-
dc.subject.keywordPlusVOLUME-
dc.type.docTypeArticle-
dc.identifier.kciidART003287083-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClasskci-
dc.relation.journalWebOfScienceCategoryClinical Neurology-
dc.relation.journalWebOfScienceCategorySurgery-
dc.relation.journalResearchAreaNeurosciences & Neurology-
dc.relation.journalResearchAreaSurgery-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.